Influenza

A new streamlined method for purifying lab-grown viruses could accelerate vaccine production, allowing manufacturers to respond rapidly to emerging viral threats

Understanding how closely related coronaviruses circulate seasonally could impact the timing of vaccination against SARS-CoV-2.

A*STAR researchers have identified specific sites in the surface protein of influenza viruses that allow the pathogen to adapt to different host organisms.

The host immune system has a limited impact on the evolution of the influenza virus, A*STAR researchers find.

Infiltrating self-defense cells provoke kidney failure in a chronic autoimmune disease

A biosensor capable of sensitively detecting influenza viruses has potential for improving clinical diagnosis of Influenza A

A more efficient production process for influenza vaccines could help to cope with future pandemics

A decade after the opening of Biopolis, Singapore’s premier biomedical sciences research hub, A*STAR’s multifaceted activities are spurring discovery and innovation with a global reach

A*STAR’s new vaccine, based on a virus-like particle technology created by Cytos Biotechnology AG, could strengthen Singapore’s ability to tackle influenza pandemics

A computational algorithm for tracking influenza viral ancestry outperforms even human experts

A silicon-based microfluidic chip that distinguishes different viral strains shows potential for the quick on-site diagnosis of infectious diseases

A strain of H1N1 influenza virus that rapidly develops resistance to the antiviral drug oseltamivir has emerged